Elsevier Honors the 2013 Nobel Laureates

Amsterdam, October 17, 2013 /3BL Media/ – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that in honor of the 2013 Nobel Laureates it has launched its Nobel Prize tribute website (www.elsevier.com/nobel).The site provides an overview of the Laureates’ ground-breaking research as well as their connections with Elsevier. In addition, free access is provided to some of their most influential research papers published in Elsevier journals.

Ron Mobed, CEO of Elsevier, said, “We are honored to have had the opportunity to work with these remarkable scholars. Over the years we have been privileged to see their connections to Elsevier either through publishing their ground-breaking work in our journals and books, or through their efforts as editors, editorial board members and reviewers. We wholeheartedly congratulate all winning 2013 Nobel Laureates and thank them for their contributions, not only to Elsevier, but to society as a whole.”

Elsevier is proud to recognize the Nobel laureates’ revolutionary research:

Medicine: Dr. James E. Rothman, Dr. Randy W. Schekman and Dr. Thomas C. Südhof were jointly awarded the 2013 Nobel Prize in Medicine or Physiology “for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells”. They revealed the critical process of the movement of molecules through cells, paving the way for targeted medication for a variety of neurological and immunological diseases, such as diabetes, autism and Parkinson’s disease.

James Rothman was the Editor for Methods in Enzymology (1992 edition) and is an Editorial Board Member for FEBS Letters. Dr. Schekman published in among others Cell, Developmental Cell, Cell Biology and Cell Host & Microbe. He has also been awarded the 2013 Otto Warburg medal by the German Society for Biochemistry and Molecular Biology (GBM). Dr. Südhof published in Cell and Neuron, and was a contributing author to Handbook of Cell Signaling, Parkinson’s Disease and others.

Physics: Dr. François Englert and Dr. Peter W. Higgs were jointly awarded the 2013 Nobel Prize in Physics for their “theoretical discovery of a mechanism that contributes to our understanding of the origin of mass of subatomic particles, and which recently was confirmed through the discovery of the predicted fundamental particle, by the ATLAS and CMS team experiments at CERN's Large Hadron Collider". In 1964, Dr. Englert and Dr. Higgs, independently of each other, proposed a similar theory of how matter acquires mass. A half century later, in July 2012, their proposed theory was confirmed at CERN in Switzerland with the discovery of the Higgs Boson.

Dr. Englert and Dr. Higgs frequently published in Physics Letters B and Nuclear Physics B. Dr.Englert was also a contributing author to Recent Developments in Quantum Field Theory. The two ground-breaking CERN studies in 2012 confirming the Higgs Boson were published in Physics Letters B.

Chemistry: Dr. Martin Karplus, Dr. Michael Levitt and Dr. Arieh Warshel were jointly awarded the 2013 Nobel Prize in Chemistry "for the development of multiscale models for complex chemical systems.” They developed new computer models combining quantum and Newtonian physics for the first time. Their method of modeling has widespread applications in that it can be used to model virtually every chemical reaction.

Dr. Karplus is Editorial Board member of Structure and has published in among others Chemical Physics Letters, Biophysical Chemistry and Biophysical Journal. Dr. Levitt is an Editorial Board Member of Current Opinion in Structural Biology and has published in Current Opinion in Structural Biology, Structure, and Biophysical Journal. Dr. Warshel has published in among others, Biophysical Journal, BBA – Bioenergetics, Chemical Physics Letters and FEBS Letters.

Economics: Dr. Eugene F. Fama, Dr. Lars Peter Hansen and Dr. Robert J. Shiller were jointly awarded the 2013 Sveriges Riksbank Prize in Economic Sciences for “their empirical analysis of asset prices.” They developed a method of analyzing stock and bond prices over the course of longer periods. With their research, they have created a method to make accurate assumptions about asset prices, allowing investors and individuals to make informed decision on how to use their savings.

Dr. Fama is an Advisory Editor for the Journal of Financial Economics and has published in Journal of Financial Economics and the Journal of Monetary Economics. Dr. Hansen is a Co-Editor for Handbook of Financial Econometrics: Tools and Techniques and has published in Journal of Economic Theory, Journal of Economic Dynamics and Control, Journal of Econometrics and others. Dr. Shiller’s work can be found in Journal of the Japanese and International Economies, Economics Letters, Journal of Econometrics, Journal of Monetary Economics and Journal of Economic Behavior & Organization.

For more information about the 2013 Nobel Laureates, their awarded research and connections with Elsevier go to: www.elsevier.com/nobel

# # #

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Sacha Boucherie
Press Officer, Elsevier
+31 20 4853564
s.boucherie@elsevier.com